Johanna Holldack
Director/Board Member bei PHOTOCURE ASA
Vermögen: - $ am 31.03.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Madiha Derouazi | M | 51 |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | 12 Jahre |
| Erik Dahl | M | - | 12 Jahre | |
| Neal Shore | M | - | 2 Jahre | |
| Dylan Hallerberg | M | - | - | |
| Daniel Schneider | M | - | 6 Jahre | |
| Anders Neijber | M | - | 3 Jahre | |
| Patricia Kelly | F | - | 4 Jahre | |
| Susanne Strauss | M | - | 4 Jahre | |
| Andreas Wallnöfer | M | 63 |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
| Karin Hehenberger | M | 52 |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
| Pierre Armand Morgon | M | 61 |
Kupando GmbH
 Kupando GmbH BiotechnologyHealth Technology Kupando GmbH is a German biopharmaceutical company that develops agonists to stimulate innate immunity. The company is based in Schoenefeld, Germany. The company was founded in 2018 by Johanna Holldack, who has been the CEO since 2018. | 3 Jahre |
| Malene Brondberg | F | 51 | - | |
| Frank Kalkbrenner | M | - |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
| Grete Hogstad | F | 68 | 19 Jahre | |
| Geoffrey Coy | M | - | 5 Jahre | |
| Roberto Maj | M | - |
Kupando GmbH
Kupando GmbH BiotechnologyHealth Technology Kupando GmbH is a German biopharmaceutical company that develops agonists to stimulate innate immunity. The company is based in Schoenefeld, Germany. The company was founded in 2018 by Johanna Holldack, who has been the CEO since 2018. | - |
| Maja Bergmann | F | - | 5 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Kjetil Hestdal | M | 64 | 21 Jahre | |
| Gwen Melincoff | M | 72 | 3 Jahre | |
| Tom Edward Pike | M | 64 | 6 Jahre | |
| Jan Hendrik Egberts | M | 65 | 6 Jahre | |
| Synne Hermansen Røine | F | 45 | 6 Jahre | |
| Anne Hovi Worsøe | F | 60 | - | |
| Gry Stensrud | M | 54 | 15 Jahre | |
| Anders Tuv | M | 46 | - | |
| Jeremy Bahr | M | - | - | |
| Kari Myren | F | - | 6 Jahre | |
| Einar Antonsen | M | - | 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Norwegen | 22 | 78,57% |
| Schweiz | 4 | 14,29% |
| Deutschland | 2 | 7,14% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Johanna Holldack
- Persönliches Netzwerk
